New Data Reveals Acoramidis Impact on Serum Transthyretin and Cardiovascular Outcomes
Wednesday, 29 May 2024, 17:12
New Data Reveals Acoramidis Impact on Serum Transthyretin and Cardiovascular Outcomes
The latest findings from BridgeBio Pharma's Phase 3 ATTRibute-CM Study presented at ISA showcase the significant impact of Acoramidis in increasing serum Transthyretin levels. This increase is directly linked to improved cardiovascular outcomes, indicating a promising potential for managing cardiovascular health through targeted therapies. The study's results highlight the importance of optimizing Transthyretin levels for better heart health, opening up new avenues for treating cardiovascular conditions in the future.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.